Pneumonia
Jump to navigation
Jump to search
C-reactive protein and procalcitonin
Several studies have compared the c-reactive protein and procalcitonin in the prognosis of pneumonia.[1][2][3][4] The procalcitonin may[5][4][2][3] or may not[1] be more accurate.
- ↑ 1.0 1.1 Holm A, Pedersen SS, Nexoe J, et al. (July 2007). "Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care". Br J Gen Pract 57 (540): 555–60. PMID 17727748. PMC 2099638. [e]
- ↑ 2.0 2.1 Müller B, Harbarth S, Stolz D, et al. (2007). "Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia". BMC Infect. Dis. 7: 10. DOI:10.1186/1471-2334-7-10. PMID 17335562. PMC 1821031. Research Blogging.
- ↑ 3.0 3.1 Brunkhorst FM, Al-Nawas B, Krummenauer F, Forycki ZF, Shah PM (February 2002). "Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia". Clin. Microbiol. Infect. 8 (2): 93–100. PMID 11952722. [e]
- ↑ 4.0 4.1 Krüger S, Ewig S, Marre R, et al. (February 2008). "Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes". Eur. Respir. J. 31 (2): 349–55. DOI:10.1183/09031936.00054507. PMID 17959641. Research Blogging.
- ↑ Niederman MS (December 2008). "Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin". Clin. Infect. Dis. 47 Suppl 3: S127–32. DOI:10.1086/591393. PMID 18986278. Research Blogging.